Consumption of C3 via the classical and alternative complement pathways by sera and synovial fluids from patients with rheumatoid arthritis.
Five sera and four synovial fluids from patients with rheumatoid arthritis were found to contain substances which consumed hemolytic C3 in normal human serum (NHS) and in normal guinea pig serum (NGPS). These fluids were then tested for ability to activate the alternative pathway by incubating them with NHS containing MgEGTA and C4 deficient GPS. All sera and two synovial fluids depleted C3 in these reagents, indicating direct activation by the alternative pathway. Density gradient ultracentrifugation demonstrated C3 fixing activity in some specimens in the greater than 19s regions. These substances may also activate complement similarly in vivo and participate in the development of inflammatory processes associated with this disease.
D000328:Adult; D000368:Aged; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology*; D003181:Complement C4 / Q000172:deficiency; D003168:Complement Fixation Tests; D003170:Complement Pathway, Alternative; D003171:Complement Pathway, Classical; D004533:Egtazic Acid / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D013582:Synovial Fluid / Q000276:immunology*
D003176:Complement C3; D003181:Complement C4; D007075:Immunoglobulin M; D004533:Egtazic Acid